Ausgabe 7/2016
Inhalt (12 Artikel)
Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas
Pamela L. Beatty, Rick van der Geest, Jana G. Hashash, Takashi Kimura, Dmitriy Gutkin, Randall E. Brand, Olivera J. Finn
Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors
Anja Derer, Benjamin Frey, Rainer Fietkau, Udo S. Gaipl
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Mohammad H. Saleh, Lei Wang, Michael S. Goldberg
PD-L1-specific T cells
Shamaila Munir Ahmad, Troels Holz Borch, Morten Hansen, Mads Hald Andersen
Lessons learned from cancer vaccine trials and target antigen choice
Lisa H. Butterfield
High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy
Suresh Gopi Kalathil, Yasmin Thanavala
Tumor-derived factors modulating dendritic cell function
Jinbao Zong, Anton A. Keskinov, Galina V. Shurin, Michael R. Shurin
Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice
Anna K. Kozlowska, Kawaljit Kaur, Paytsar Topchyan, Anahid Jewett
How frequently are predicted peptides actually recognized by CD8 cells?
Ioana Moldovan, Oleg Targoni, Wenji Zhang, Srividya Sundararaman, Paul V. Lehmann
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Michal Baniyash
Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells
Leena Chaudhuri, Rupesh K. Srivastava, Ferdynand Kos, Protul A. Shrikant
Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia
Natalia Aptsiauri, Anahid Jewett, Arthur A. Hurwitz, Michael R. Shurin, Viktor Umansky